With complements from ANCA mice.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.Clinical rheumatology · 2021
   Pooled it
2. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.Journal of the American Society of Nephrology : JASN · 2017
   Trial
3. Complement as a major mediator of ANCA vasculitis and a target for precision therapy.Expert review of clinical immunology · 2025
   Review
4. Identification of differentially expressed genes and pathways in kidney of ANCA-associated vasculitis by integrated bioinformatics analysis.Renal failure · 2022
   Article
5. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy.Clinical and experimental immunology · 2020
   Review
6. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.JMIR research protocols · 2020
   Article
7. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives.Internal and emergency medicine · 2017
   Review
8. Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis.Clinical journal of the American Society of Nephrology : CJASN · 2015
   Article
9. Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.Journal of the American Society of Nephrology : JASN · 2015
   Review

Corrections and comments

• Comment on
  C5a receptor (CD88) blockade protects against MPO-ANCA GN.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as